Our key figures
Our revenue decreased by 0.6% (decrease 1.5% organically). We delivered profitability of 19.1% adjusted EBITDA margin and a free cash flow of CHF 39.6 million.
Share of revenue by business unit
2024
Share of revenue by business unit
2023
Key figures
|
millions of CHF |
|
2024 |
|
% of revenue |
|
+/–% change |
|
2023 |
|
% of revenue |
|
Revenue |
|
483.9 |
|
100.0% |
|
–0.6% |
|
486.6 |
|
100.0% |
|
Organic revenue growth 1) |
|
|
|
|
|
–1.5% |
|
|
|
|
|
Gross profit |
|
159.7 |
|
33.0% |
|
1.3% |
|
157.6 |
|
32.4% |
|
Operating income (EBIT) |
|
12.9 |
|
2.7% |
|
–19.0% |
|
16.0 |
|
3.3% |
|
EBITDA |
|
74.5 |
|
15.4% |
|
0.2% |
|
74.4 |
|
15.3% |
|
Adjusted EBITDA |
|
92.5 |
|
19.1% |
|
–0.7% |
|
93.1 |
|
19.1% |
|
Net income |
|
–6.4 |
|
–1.3% |
|
n/a |
|
0.7 |
|
0.1% |
|
Free cash flow (FCF) |
|
39.6 |
|
|
|
n/a |
|
3.4 |
|
|
|
Operating net cash flow (ONCF) |
|
61.0 |
|
|
|
239.8% |
|
17.9 |
|
|
|
Capital expenditure, net (capex, net) |
|
44.3 |
|
|
|
–33.3% |
|
66.3 |
|
|
|
Net debt as of December 31 |
|
205.3 |
|
|
|
–6.3% |
|
219.0 |
|
|
|
Net debt adjusted EBITDA ratio as of December 31 |
|
2.22 |
|
|
|
–5.6% |
|
2.35 |
|
|
|
Employees (number of full-time equivalents) as of December 31 |
|
2’684 |
|
|
|
1.0% |
|
2’658 |
|
|
1) Adjusted for currency effects.
Our KEY Figures
revenue in 2024
adjusted EBITDA margin
free cash flow generated in 2024
Stock market information
|
|
|
2024 |
|
2023 |
|
Registered share (in CHF) |
|
|
|
|
|
– high |
|
18.68 |
|
26.38 |
|
– low |
|
8.28 |
|
16.45 |
|
– year-end |
|
8.80 |
|
19.00 |
|
|
|
|
|
|
|
Market capitalization as of December 31 |
|
|
|
|
|
– number of shares issued |
|
41’262’370 |
|
41’262’370 |
|
– in millions of CHF |
|
363.1 |
|
784.0 |
|
– in percentage of equity |
|
83% |
|
168% |
|
|
|
|
|
|
|
P/E ratio as of December 31 |
|
–48.7x |
|
2674.3x |
|
Dividend yield as of December 31 |
|
5.7% |
|
2.6% |
Data per share
|
CHF |
|
2024 |
|
2023 |
|
Net income attributable to a shareholder of medmix Ltd |
|
–0.18 |
|
0.01 |
|
Equity attributable to a shareholder of medmix Ltd |
|
10.60 |
|
11.30 |
|
Ordinary dividend |
|
0.50 1) |
|
0.50 |
|
Payout ratio |
|
–277% |
|
7’038% |
|
Average number of shares outstanding as of December 31 |
|
40’779’842 |
|
40’868’426 |
1) Proposal to the Annual General Meeting.
Shareholder structure as of December 31, 2024
|
Number of shares |
|
Number of shareholders |
|
Shareholding |
|
1–100 |
|
2’485 |
|
0.3% |
|
101–1'000 |
|
3’585 |
|
3.6% |
|
1'001–10'000 |
|
1’019 |
|
7.0% |
|
10'001–100'000 |
|
102 |
|
6.7% |
|
More than 100'000 |
|
20 |
|
53.0% |
|
Total registered shareholders and shares (excluding treasury shares medmix Ltd) |
|
7’211 |
|
70.6% |
Shareholder structure as of December 31, 2023
|
Number of shares |
|
Number of shareholders |
|
Shareholding |
|
1–100 |
|
2’883 |
|
0.4% |
|
101–1'000 |
|
4’187 |
|
3.9% |
|
1'001–10'000 |
|
783 |
|
5.1% |
|
10'001–100'000 |
|
92 |
|
6.2% |
|
More than 100'000 |
|
22 |
|
52.6% |
|
Total registered shareholders and shares (excluding treasury shares medmix Ltd) |
|
7’967 |
|
68.2% |
Global reach, local presence
